NCT03693612 2024-08-28GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid TumorsGlaxoSmithKlinePhase 1/2 Completed26 enrolled 47 charts
NCT03522584 2023-06-12Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaUniversity of WashingtonPhase 1/2 Terminated6 enrolled 8 charts
NCT02643303 2022-12-02A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer ResearchPhase 1/2 Completed58 enrolled 24 charts